두경부암의 EGFR 표적 치료

참고문헌 (102)

1. "Postoperative irradiation with or without concomi-tant chemotherapy for locally advanced head and neck cancer", 350(19), pp.1945~1952 (2004)
2. "Randomized comparison of cisplatin, methotr-exate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck", pp.234~8 (1994)
3. "Randomized trial of neoadjuvant cisplatin and fluor-ouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer", 13(6), pp.1493~1500 (1995)
4. "A phase III randomized study comparing cisplatin and flu-orouracil as single agents and in combination for advanced squa-mous cell carcinoma of the head and neck", pp.49~139 (1992)
5. "Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma", 40(5), pp.525~531 (2004)
6. "Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cel carcinoma of the head and neck", 11(7), pp.845~849 (2000)
7. "Field cancerization in oral stratified squamous epithelium; Clinical implications of multicentric origin" (1953)
8. "Signaling through the epidermal growth factor receptor during the development of malignancy", 102(1), pp.37~46 (2004)
9. "Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor", 376(6538), pp.337~341 (1995)
10. "Strain-dependent epithelial defects in mice lacking the EGF receptor", 269(5221), pp.234~238 (1995)
11. "Targeted disruption of mouse EGF receptor: Effect of ge-netic background on mutant phenotype", 269(5221), pp.230~234 (1995)
12. "Signal transduction through MAP kinase cascades", 74, pp.49~139 (1998)
13. "Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention", pp.945~54 (1993), Clin Cancer Res 2002;8
14. "Protein kinase B (c-Akt) in phosphatidyli-nositol-3-OH kinase signal transduction", 376(6541), pp.599~602 (1995)
15. "PI3K", Akt signalling pathway and cancer, 2004, pp.30(2), 193~204
16. "Protein kinase C: A paradigm for regula-tion of protein function by two membrane-targeting modules", 1376(2), pp.155~172 (1998)
17. "Epidermal growth factor receptor-stimulated activation of pho-spholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma", 63(17), pp.5629~5635 (2003)
18. "STAT signaling in head and neck cancer", 19(21), pp.2489~2495 (2000)
19. "The role of STATs in transcriptional con-trol and their impact on cellular function", 19(21), pp.2468~2473 (2000)
20. "Evaluation of TGF-alpha and EGFR ex-pression in oral leukoplakia and oral submucous fibrosis by quantita-tive immunohistochemistry", pp.284~92 (1993)
21. "Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention", 8(4), pp.945~954 (2002)
22. "Constitutive activation of Stat3 by the Src and JAK tyrosine kina-ses participates in growth regulation of human breast carcinoma cells", 20(20), pp.2499~2513 (2001)
23. "Src kinases mediate STAT growth pathways in squamous cell car-cinoma of the head and neck", 278(34), pp.31574~31583 (2003)
24. "Epidermal growth factor receptor (EGFR) transactiva-tion by estrogen via the G-protein-coupled receptor, GPR30: A novel signaling pathway with potential significance for breast cancer", 80(2), pp.231~238 (2002)
25. "Phosphorylation of TNF-alpha converting enzyme by gastrin-relea-sing peptide induces amphiregulin release and EGF receptor activa-tion", 103(18), pp.6901~6906 (2006)
26. "Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer" (1987)
27. "Asynchronous modu-lation of transforming growth factor alpha and epidermal growth fac-tor receptor protein expression in progression of premalignant lesions to head and neck squamous cel carcinoma", 4(1), pp.13~20 (1998)
28. "Evaluation of TGF-alpha and EGFR ex-pression in oral leukoplakia and oral submucous fibrosis by quantita-tive immunohistochemistry", 61(4), pp.284~292 (2001)
29. "Retinoic acid normalizes the 195increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines", pp.237~40
30. "The localization of transforming growth factor alpha and epidermal growth factor receptor in stromal and epithelial compartments of developing human prostate and hy-perplastic, dysplastic, and carcinomatous lesions", 29(7), pp.668~675 (1998)
31. "The ex-pression of type I growth factor receptors in the squamous neoplastic changes of uterine cervix", 73(1), pp.62~71 (1999)
32. "Epider-mal growth factor receptor family in lung cancer and premalignancy", 29, pp.3~14 (2002)
33. "Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1", pp.13176~80
34. "Intere-thnic diference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism", pp.1009~12, Clin Cancer Res 2003;9
35. "The epidermal growth factor receptor in gliobla-stoma: Genomic amplification, protein expression, and patient survi-val data in a therapeutic trial", 14(3), pp.169~174 (1995)
36. "Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck", 78(6), pp.1284~1292 (1996)
37. "Retinoic acid normalizes the 195increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines", 2(2), pp.237~240 (1996)
38. "Quan-titation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malig-nant oral epithelial lesions", 37(7), pp.599~604 (2001)
39. "Mutant epidermal growth factor receptors as targets for cancer therapy", pp.91~102
40. "Length and loss of heterozygosity of an intron 1 poly-morphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression", 60(4), pp.854~857 (2000)
41. "Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1", 274(19), pp.13176~13180 (1999)
42. "Intere-thnic diference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism", 9(3), pp.1009~1012 (2003)
43. "A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter", 65(1), pp.46~53 (2005)
44. "The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth fac-tor receptor", 69(7), pp.4390~4398 (1995)
45. "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer", pp.2787~9
46. "The type III epi-dermal growth factor receptor mutation", 12(6), pp.745~760 (2001)
47. "Mutant epidermal growth factor receptors as targets for cancer therapy", 2(2), pp.91~102 (2002)
48. "Epidermal gro-wth factor-related peptides and their receptors in human malignan-cies", 19(3), pp.183~232 (1995)
49. "Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival", 90(11), pp.824~832 (1998)
50. "C-erbB rece-ptors in squamous cell carcinomas of the head and neck Cinical significance and correlation with matrix metalloproteinases and va-scular endothelial growth factors", pp.73~80
51. "The epidermal growth factor receptor as a target for cancer therapy", 8(1), pp.3~9 (2001)
52. "EGFR and cancer prognosis", 37, pp.S9~S15 (2001)
53. "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer", 21(14), pp.2787~2789 (2003)
54. "Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145", pp.3666~9
55. "A sensitive enzyme-linked immunosorbent assay used for quantitation of epidermal growth factor receptor protein in head and neck carci-nomas: Evaluation, interpretations and limitations", 72(6), pp.1487~1493 (1995)
56. "Prognostic value of EGFR and TGF-alpha in early laryngeal can-cer treated with radiotherapy", 106(7), pp.884~888 (1996)
57. "Com-bination of EGFR, HER-2", neu, and HER-3 is a stronger predic-tor for the outcome of oral squamous cell carcinoma than any indivi-dual family members, 1999.12, pp.5(12), 4164~4174
58. "C-erbB rece-ptors in squamous cell carcinomas of the head and neck: Cinical significance and correlation with matrix metalloproteinases and va-scular endothelial growth factors", 38(1), pp.73~80 (2002)
59. "Differential modulation of proliferation matrix metaloproteinase ex-pression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands", pp.631~9
60. "Local recurrence in head and neck cancer: Rela-tionship to radiation resistance and signal transduction", 8(3), pp.885~892 (2002)
61. "Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib Superiority over single-agent receptor targeting", more and the mo(-bue g -clonal antibody cetuximab), pp.6487~501, Clin Cancer Res 204;10
62. "Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145", 56(16), pp.3666~3669
63. "Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radio-sensitivity in squamous cell carcinomas of the head and neck", 59(8), pp.1935~1940 (1999)
64. "Induction of apoptosis and activation of the caspase cascade by anti-EGF recep-tor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity", 82(12), pp.1991~1999 (2000)
65. "Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice", 4(12), pp.2957~6 (1998)
66. "Anti-epidermal growth factor receptor antibody C25 inhibits angiogenesis in human transitional cell carcinoma growing ortho-topically in nude mice", 5(2), pp.257~265 (1999)
67. "Differential modulation of proliferation, matrix metaloproteinase ex-pression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands", 17(7), pp.631~639 (1999)
68. "Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation", pp.255~68
69. "Humanization of a mouse monoclonal antibody by CDR-grafting The importance of framework residues on loop conformation", pp.773~83
70. "Dual-agent molecular targeting of the epidermal growth factor rece-ptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor", 64(15), pp.5355~5362 (2004)
71. "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck", 354(6), pp.567~578 (2006)
72. "Impact of the EGFR inhibitor C225 on wound healing in advanced head & neck cancer patients undergoing neck disection", 22, pp.881~ (2003)
73. "Improved Preservation of Larynx with the Adition of Cetuximab to Radiation for Cancers of the Larynx and Hypopharynx", 23(16S), pp.5533~ (2005)
74. "Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with plati-num-based chemotherapy in patients with platinum-refractory meta-static and", or recurent squamous cel carcinoma of the head and neck, 2005, pp.23(24), 5568~5577
75. "Ph-ase II randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic", recurrent head and neck can-cer: An Eastern Cooperative Oncology Group study, 2005, pp.23(34), 8646~8654
76. "Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation", 30(3), pp.255~268 (2004)
77. "Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor", 22(1), pp.175~184 (2004)
78. "Use of the humanized anti-epidermal growth factor receptor mono-clonal antibody h-R3 in combination with radiotherapy in the treat-ment of locally advanced head and neck cancer patients", 22(9), pp.1646~1654 (2004)
79. "Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy", 38(1), pp.17~23 (2001)
80. "A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expresing tumor cells in vitro and in vivo", 76(1), pp.154~163 (1998)
81. "Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms", 6(5), pp.1936~1948 (2000)
82. pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhi-bitor, , 1997, 877~887
83. "Epidermal growth factor receptor (HER1) tyrosine ki-nase inhibitor ZD1839 (Iressa) inhibits HER2", neu (erbB2)-overex-presing breast cancer cels in vitro and in vivo, 2001, pp.61(24), 8887~8895
84. "Tyrosine kinase inhibitors-ZD1839(Iressa)", 13(6), pp.491~498 (2001)
85. "Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor", 6(5), pp.2053~2063 (2000)
86. "Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasi-veness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa)", 2(4), pp.345~351 (2003)
87. Magne N, "Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839(Iresa )", 86(9), pp.1518~1523 (2002)
88. Moasser MM, "The tyrosine kinase inhibitor ZD1839(Iresa ) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpresing tumor cells", 61(19), pp.7184~7188 (2001)
89. Magne N, "Sequence-dependent effects of ZD1839 (Iressa) in com-bination with cytotoxic treatment in human head and neck cancer", 86(5), pp.819~827 (2002)
90. Huang SM, "Modulation of radiation response and tumor-induced angiogenesis after epidermal growth fac-tor receptor inhibition by ZD1839 (Iressa)", 62(15), pp.4300~4306 (2002)
91. Baselga J, "Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types", 20(21), pp.4292~4302 (2002)
92. Herbst RS, "Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial", 20(18), pp.3815~3825 (2002)
93. Cohen EE, "Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck", 21(10), pp.1980~1987 (2003)
94. Inoue A, "Severe acute interstitial pneumonia and gefitinib", 361(9352), pp.137~139 (2003)
95. Ohyanagi F, "Acute gefitinib-induced pneumonitis", 9(5), pp.406~409 (2004)
96. "Preclinical studies with Erlotinib(Tar-ceva)", 30, pp.15~24 (2003)
97. "Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies", 19(13), pp.3267~3279 (2001)
98. "Multicenter phase I study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck", 22(1), pp.77~85 (2004)
99. "Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter", 90(14), pp.1080~1087 (1998)
100. "Tissue distribution of liposome-mediated epidermal growth", 10(7), pp.518~528 (2003)
101. "Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo", 86(2), pp.269~275 (2000)
102. "Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha", 74(6), pp.853~862 (1996)

관련 논문AI추천